Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.

Seminars in oncology

Volumn 24, Issue 1 Suppl 5, 1997, Pages

  ten Bokkel Huinink, W ^a   Carmichael, J ^a   Armstrong, D ^a   Gordon, A ^a   Malfetano, J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; PACLITAXEL; PLATINUM; TOPOTECAN;

CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; OVARY TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REMISSION; REVIEW; SAFETY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MULTICENTER STUDIES; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; REMISSION INDUCTION; SAFETY; SURVIVAL RATE; TOPOTECAN;

EID: 0031064224     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)